Form 4: Bausch & Lomb Executive Receives Stock Options and Restricted Stock Units

Sentiment:

SEC Filing


Andrew J. Stewart, a Bausch & Lomb executive, was granted stock options and restricted stock units (RSUs) under the company's 2022 Omnibus Incentive Plan.

Summary

  • Andrew J. Stewart, President, Global Pharmaceuticals and International Consumer at Bausch & Lomb Corp, filed a Form 4 on March 1, 2024.
  • The filing reports the grant of 50,813 non-qualified stock options with an exercise price of $16.85, vesting in equal installments over three years and expiring in ten years.
  • Stewart also received 16,778 restricted stock units (RSUs) that vest one-third annually over three years.
  • Vested RSUs will be settled in common shares of Bausch & Lomb Corporation.
  • Following these transactions, Stewart directly owns 49,928 common shares and 50,813 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management with shareholder interests.

Positives

  • The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
  • The vesting schedule encourages continued service and performance by the executive.

Future Outlook

The stock options and RSUs are subject to continued service and the terms of the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.

Industry Context

This is a standard practice for incentivizing executives in publicly traded companies.

Comparison to Industry Standards

  • Stock option and RSU grants are common forms of executive compensation in the pharmaceutical and consumer goods industries.
  • Companies like Johnson & Johnson, Novartis, and Procter & Gamble also utilize similar incentive plans to align executive interests with shareholder value.

Stakeholder Impact

  • Shareholders may view the grants positively as they incentivize management to improve company performance.
  • Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates

DateDescription
02/28/2024Date of the transaction (grant of stock options and RSUs).
03/01/2024Date the Form 4 was filed.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.